Pharvaris 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, and thank you for joining Guggenheim's 3rd annual Healthcare Innovation Conference. I am Debjit, one of the therapeutic analysts, and joining me on stage are Peng Lu, president, and Maggie Beller, the head of IR from Pharvaris. Thank you both for making time for us.
Thanks for having us. Who wants to take the first one?
Maybe for people who have not heard the story, a very quick intro would be helpful, and then we can dive into Q&A.
Yeah, maybe I can start. I'm Peng Lu here. I'm the president of Pharvaris. Actually, I'm the physician scientist, have been working in HAE over a decade. Our motivation is how we can translate the novel science to really help the patients and really address what the patient need. That's exactly why we built up Pharvaris here. Pharvaris actually is a company really dedicated to developing oral treatments for HAE or maybe potentially bradykinin-mediated patients there. Currently, we have our leading compound, deucrictibant, and have one molecule with two different formulations. One formulation absorbed in upper GI and would be considered for on-demand treatment to help the HAE patients, and the other is the prophylactic formulation, and to be considered for the prevention of the attacks for the HAE or eventually for the bradykinin-mediated angioedema patients.
Currently, indeed, in the exciting moment for the company, and we are very close to bring deucrictibant for our patients to give them greater control and simplicity here.
Yep. Just a quick update across the business. We read out our pivotal phase III on-demand data in December of last year. We have a PDUFA date for that on April 23, 2027. That will be for deucrictibant for the on-demand treatment of HAE attacks. Additionally, we just read out our pivotal CHAPTER-3 prophylactic data in September of this year, and we are on track to submit an NDA for that. As Peng mentioned, we are hoping to submit it for bradykinin-mediated angioedema because we are also going to be reading out top-line data from our CREATE study, which is the deucrictibant for the prevention of acquired angioedema attacks. That will be in the first quarter of next year. Lots of really exciting things happening for Pharvaris right now.
Let us unpack that a little bit, the CREATE data. If that reads out positively, you are going to wait for that data before you submit the NDA for deucrictibant XR, right?
The rate-limiting step for the NDA is actually our open-label extension data, the safety database from CHAPTER-4. It happens to be that the CREATE data will align with our timing for the submission of the HAE NDA. By combining the AAE dataset with our HAE dataset, we can actually apply for a broader label of bradykinin-mediated angioedema, and that may open us up to priority review.
So that's what I was going to get at. How important are the CREATE data for a priority review versus a standard review?
Yeah, maybe I can help address it. Currently, both our CHAPTER-4 study and CREATE study, as Maggie introduced, on track here, that we expect we will move forward at very simultaneous time. But as mentioned, there is no bundling together here, that no matter for HAE or CREATE, that acquired angioedema study, is we're discussing with the agency. But as Maggie mentioned, for the deucrictibant, especially for our prophylactic treatment, that acquired patients, they have no any treatment available. From the whole community, they have strong desire for the treatment available for them. That's exactly we try all the best to give these patients that available treatment as soon as possible. That's why we targeted to submit both HAE and acquired angioedema in parallel at the same time for bradykinin-mediated angioedema, the more broad umbrella term here.
Got it. There's not much of a clinical debate right now, given that the CHAPTER-3 had injectable-like efficacy for an oral product. How are you guys internally thinking about the commercial landscape, given that this is a complicated, or not complicated, but it's a crowded commercial landscape, right? How are you thinking about what could happen, say, 12 months from now?
Actually, maybe I can start here. That's definitely, that currently, as mentioned, the next year is incredible exciting for Pharvaris. And currently, that we have built up the commercial team, especially U.S. commercial team. As mentioned, that's a highly competitive field, but meanwhile, we have very strong team and have that no matter for our R&D team and the commercial team have deep root in the HAE field, have very good connection with the whole community and also with the patient advocacy group here. Therefore, so far, we are very proud, right? We have almost 80%, 90% commercial team on board, and we are quite ready to move towards that our, knock on wood, get the PDUFA, that get approval in U.S., that April next year, and get a strong launch there.
Maybe I can add a little bit just to the dynamics between some of the competitors in this space. In the on-demand side of the business, we really feel that orals will dominate, seeing as you need to treat an attack after it happens to be able to address the signs and symptoms. The decreased treatment burden that one has when treating with an oral as opposed to an injectable is highly prefers an oral, because it is just easier to take, it is more discreet. The current injections sting when you have to inject them. One of the things that deucrictibant brings to the table is that it utilizes the same mechanism of action as icatibant, which is the most widely used on-demand therapy right now. What we view it as is a B2 receptor antagonist, just like icatibant, but this time oral.
That is really where we see the on-demand shaking out is that orals will dominate, and we have the benefit of the same mechanism. With prophylaxis, we think that there are likely going to be a winner in the oral space and a winner in the injectable space. This is the benefit of having multiple therapies that are approved is that each patient and physician can select what is best for that person's life. As you mentioned before, we are showing injectable-like efficacy. For the first time, people are not needing to make a decision between their efficacy, their tolerability, and their convenience. Somebody can prefer an oral, or they may prefer an injectable, but now for the first time with our CHAPTER-3 data, they do not have to forego efficacy to have the convenience of an oral.
Got it. On the CHAPTER-3, when you think about the baseline, the attack rate at baseline was relatively high compared to some of the other studies. When you look through your data, does the efficacy hold up across patients with higher baseline attack rates versus those with lower?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
